side each, according to the SIOP-MMT-95 regimen. 3 The overall cumulative chemotherapy dosages prior to mobilization chemotherapy were: ifosfamide 54 g/m 2 , vincristine We report a very rapid engraftment after reinfusion of bone marrow cells derived from 'G-CSF-primed bone 25.5 mg/m 2 , actinomycin-D 9 mg/m 2 , carboplatin 3600 mg/m 2 , epirubicin 450 mg/m 2 and etoposide marrow' in a small child. As the hemopoietic recovery was equal to that seen after PBSCT, we suggest that the 900 mg/m 2 . Following a stem cell mobilizing chemotherapy course consisting of carboplatin 600 mg/m 2 , etoposide use of 'mobilized bone marrow' is a good alternative for PBSCT in children if contraindications to the collec-450 mg/m 2 and vincristine 1.5 mg/m 2 (cev in Figure 1) , the patient received G-CSF (Neupogen; 10 g/kg s.c.) After tion of PBSCT are present.
Summary:
side each, according to the SIOP-MMT-95 regimen. 3 The overall cumulative chemotherapy dosages prior to mobilization chemotherapy were: ifosfamide 54 g/m 2 , vincristine We report a very rapid engraftment after reinfusion of bone marrow cells derived from 'G-CSF-primed bone 25.5 mg/m 2 , actinomycin-D 9 mg/m 2 , carboplatin 3600 mg/m 2 , epirubicin 450 mg/m 2 and etoposide marrow' in a small child. As the hemopoietic recovery was equal to that seen after PBSCT, we suggest that the 900 mg/m 2 . Following a stem cell mobilizing chemotherapy course consisting of carboplatin 600 mg/m 2 , etoposide use of 'mobilized bone marrow' is a good alternative for PBSCT in children if contraindications to the collec-450 mg/m 2 and vincristine 1.5 mg/m 2 (cev in Figure 1) , the patient received G-CSF (Neupogen; 10 g/kg s.c.) After tion of PBSCT are present. Keywords: ABMT; PBSCT; G-CSF; mobilized bone approximately 20 days of G-CSF treatment, the WBC started rising (see Figure 1 ) and a bone marrow harvest promarrow; fibrosarcoma cedure was performed at the 24th day of G-CSF treatment. Under general anesthesia, 215 ml bone marrow was harvested from the posterior illiac crest. At that time, the child Peripheral blood stem cell (PBSC) reinfusions are freweighed 12 kg, and was 19 months old. The graft contained quently being used as a source of marrow repopulating cells 4.3 × 10 8 nucleated cells/kg, 3.2 × 10 6 CD34 + cells/kg and following myeloablative chemo-and/or radiotherapy in 80 × 10 4 CFU-GM/kg. Two months later, the patient was children with malignancies. The major advantages of treated with megadose, myeloablative chemotherapy PBSCT over autologous bone marrow transplantation (carboplatin 300 mg/m 2 and etoposide 300 mg/m 2 at days (ABMT) are the faster hemopoietic recovery after PBSCT −7 to −3, melphalan 140 mg/m 2 at day −2) followed by and the fact that no general anesthesia is needed for harvesting. However, in small children, technical difficulties related to vascular access and low blood flow are arguments to use ABMT instead of PBSCT, despite the slower hemopoietic recovery after ABMT. As suggested recently in a few studies in adults, faster recovery after ABMT with G-CSF-primed bone marrow as compared to 'steady state' bone marrow, 1,2 we used a G-CSF (Neupogen; Amgen, Breda, The Netherlands)-primed bone marrow graft in a child treated with myeloablative therapy for relapsed fibrosarcoma, that was not suited for PBSCT.
Case report
A fibrosarcoma of the foot with metastases in the inguinal and knee lymph nodes was diagnosed in our patient at the age of 4 months. Complete remission was not achieved after six courses of ifosfamide, vincristine and actinomycin-D. Subsequently, the child reached complete remission (histologically confirmed) after three courses of vincristine, may favor the use of bone marrow instead of PBSCT. For most pediatric patients in our unit, a bone marrow harvest
